Navigation Links
Did Eli Lilly Turn Wily With Regard to Their Best-selling Schizophrenia Drug?

Eli Lilly, the pharmaceutical company, is in a tight spot, defending its position against the law suits from mentally ill patients//, about the company’s best-selling schizophrenia drug, Zyprexa. The company is being blamed for undermining the health risks of the drug, which is being linked to obesity and high blood sugar.

On the basis of many supporting documents and internal communication between managers in the company, ample evidence has surfaced, that the company has indeed kept under wraps, the harmful side-effects of the drug Zyprexa.

Even the company’s published statistics which the sales representatives have been tutored to make light of, portrays statistics that about 30% of the patients consuming Zyprexa, have gained 22 pounds within a year of consuming the drug and some have gained as much as 100 pounds. The documents clearly portray the abiding worry of the company that its sales might plummet if they were honest about the drug’s effect on weight gain or blood sugar levels.

The company has not taken the allegation lightly and has completely denied it. Lilly explained that the FDA has been enabled with a clear picture of all the clinical trials and reviews regarding the usage of the drug world-wide. But documents in circulation within the company relates to an entirely different story. Apprehension regarding the drug’s side effects has been debated as early as 1999, to the extent that company bigwigs felt it could jeopardize the sales of their most popular product, if it were publicized.


AV
'"/>




Page: 1

Related medicine news :

1. Animal insulin product to be discontinued by drug major Eli Lilly
2. Eli Lilly Releases Digital Insulin Pen
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Changing Trends Regarding Insurance Cover For Weight Reduction Surgery
5. Leeches Provide Clues Regarding The Prevention Of Heart Disease
6. Legal Action against Authority Regarding Outbreak of Legionnaires’ Diseas
7. Mixed Opinion Regarding Common Medical And Engineering Entrance Test
8. Adolescents Influenced By Maternal Attitude Regarding Weight Control
9. Reforms Required With Regard To Mental Health Facilities
10. Tension between MP And the Cancer Council Head Regarding Screening Test for Male Cancer
11. A Just Published Book Promises To Guide Women Regarding Their Frequent UTI’
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
(Date:6/24/2016)... ... 2016 , ... Finally, a bruise cream that really works. Originally designed ... into the post-surgical treatment plans of a variety of other procedures including, but not ... effective for bruising and causes a rapid resolution of bruising and inflammatory changes compared ...
(Date:6/24/2016)... ... 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially launched its site, ... matching users with high quality water pipes within an ideal price range. The site ... was founded by two brothers, Nick and Mike Hunter, who use medical cannabis to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, ... organization responsible for clinical transfusion research programs and for the blood supply in ... Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently in its ...
(Date:6/23/2016)... ... June 23, 2016 , ... The Mechille Wilson Agency, ... throughout Jasper County and the surrounding region, is initiating a charity drive to assist ... raise funds earmarked for a scholarship fund that will be presented to the chosen ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: